Binder Therefor Patents (Class 514/961)
-
Patent number: 5486364Abstract: A solid dosage form, such as a pharmaceutical tablet, containing a rapidly hydratable konjac glucomannan sustained release excipient such as clarified konjac, cryogenically ground konjac and plasticized konjac. The method of making the tablets by compressing excipient and pharmaceutically active ingredient as dry powders.Type: GrantFiled: August 15, 1994Date of Patent: January 23, 1996Assignee: FMC CorporationInventors: Victor L. King, Thomas A. Wheatley, David F. Erkoboni
-
Patent number: 5466464Abstract: A solid preparation soluble in the buccal cavity, which is composed of a sugar comprising lactose and/or mannitol and 0.1-1.2 w/w%, based on the sugar, of agar and an active ingredient and has a density of 400 to 1,000 mg/ml and such a strength as to withstand the handling in the manufacture thereof. It has such a sufficient practical solubility in the buccal cavity that even the aged or children having difficulty in swallowing a solid preparation, such as a tablet, can take it. It has an exceedingly high strength as compared with conventional open matrix structures and hence can withstand satisfactorily carrying and PTP packaging.Type: GrantFiled: June 22, 1994Date of Patent: November 14, 1995Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Katsuhiro Masaki, Kazutoshi Ban
-
Patent number: 5431920Abstract: The present invention relates to a novel oral dosage form of a bisphosphonic active ingredient for use in treatment of diseases involving bone resorption and formulated in an enteric-coated form for administration to subjects exhibiting upper gastrointestinal tract sensitivity to bisphosphonic acid compounds.Type: GrantFiled: September 21, 1993Date of Patent: July 11, 1995Assignee: Merck Frosst, Canada, Inc.Inventor: Simon R. Bechard
-
Patent number: 5384130Abstract: Pharmacologically inactive spherical seed cores comprising at least 50% by weight of microcrystalline cellulose having an average degree of polymerization of 60 to 375, wherein the spherical seed cores have an average particle size of 100 to 1000 .mu.m, a tapped bulk density of at least 0.65 g/ml, an aspect ratio of at least 0.7, a water absorption capacity of 0.5 to 1.5 ml/g, and a friability of no more than 1%; spherical granules comprising the spherical seed cores coated with a powdery layer comprising active ingredients and having an outer layer of coating provided on the powdery layer; and a process for the production of spherical granules, comprising the steps of coating the spherical seed cores with powder comprising active ingredients using an aqueous binding solution, spraying an aqueous solution or suspension of a coating agent thereon, and drying the resulting coated granules.Type: GrantFiled: January 12, 1993Date of Patent: January 24, 1995Assignee: Asahi Kasei Kogyo Kabushiki KaishaInventor: Etsuo Kamada
-
Patent number: 5358941Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.Type: GrantFiled: December 2, 1992Date of Patent: October 25, 1994Assignee: Merck & Co., Inc.Inventors: Simon R. Bechard, Kenneth A. Kramer, Ashok V. Katdare
-
Patent number: 5328903Abstract: A composition for solid pharmaceutical preparations containing a vitamin D.sub.3 derivative capable of permitting the derivative to be uniformly distributed in the composition while being stabilized. The composition contains an excipient consisting of mannitol and sugar, a degradative agent consisting of hydroxypropyl cellulose, and a binder consisting of polyvinyl pyrrolidone and hydroxypropylmethyl cellulose.Type: GrantFiled: February 10, 1993Date of Patent: July 12, 1994Assignees: Taisho Pharmaceutical Co. Ltd., Sumitomo Pharmaceuticals Co. Ltd., Wisconsin Alumni Research FoundationInventors: Kuniaki Ishii, Yumiko Toriumi, Shigeru Itai, Hidefumi Hayashi, Masami Nemoto
-
Patent number: 5322698Abstract: The invention relates to a process for the preparation of a tablet or dragee composition containing a moisture-, heat- and light-sensitive compounds having monoclinic crystalline structure as active ingredients, which comprises homogenizing the active ingredient with 0.2 to 1.5 parts by weight of an anhydrous alkaline earth metal salt and 0.5 to 2.5 parts by weight of microcrystalline cellulose calculated for the active ingredient and optionally with one or more pharmaceutically acceptable carrier(s) and/or additive(s) and compressing the homogeneous mixture obtained to tablets in a manner known per se and, if desired, coating the tablet thus obtained in a manner known per se.Type: GrantFiled: June 5, 1992Date of Patent: June 21, 1994Assignee: Biogal Gyogyszergyar Rt.Inventors: Istvan Kovacs, Katalin Beke, Tibor Mathe, Judit Szilagyi, Gyorgy Bacsa, Katalin Marossy, Sandor Jancso, Levente Szendrei, Erno Orban, Margit Simo, Margit Biblo, Dorottya Bobak, Jozsef Lango
-
Patent number: 5310728Abstract: A method for treating corneal endothelial wounds comprises administering TGF-.alpha. to the region of the wound in an amount sufficient to promote the healing of endothelial cells.TGF-.alpha. advantageously is administered into the anterior chamber during ophthalmic surgical procedures, such as during intra-ocular lens implantation. The TGF-.alpha. preferably is administered as an active ingredient in an ophthalmological viscoelastic composition which improves the residence time of the growth factor in the anterior chamber.Type: GrantFiled: July 23, 1992Date of Patent: May 10, 1994Assignee: Chiron Ophthalmics, Inc.Inventors: Robert W. Shimizu, Gregory S. Schultz
-
Patent number: 5292519Abstract: The use of a starch obtained from a plant source that is homozygous in a white recessive gene, such as white common corn starch, has superior compression and ejection forces compared to commercial disintegrantants/binders. The starch derived from common corn containing the homozygous white recessive gene was also found to have comparable whiteness to commercial bleached corn starches used in tableting.Type: GrantFiled: April 10, 1992Date of Patent: March 8, 1994Assignee: American Maize Technology, Inc.Inventors: David J. Mauro, Frances L. Turnak
-
Patent number: 5256699Abstract: The invention provides a dispersible solid drug formulation comprising finely divided diclofenac as the free acid, from 5 to 25% by weight of a disintegrant and a pharmaceutically acceptable diluent.Type: GrantFiled: April 12, 1992Date of Patent: October 26, 1993Assignee: Ciba-Geify CorporationInventors: Lorraine M. Murphy, Graham P. Matthews
-
Patent number: 5188839Abstract: The invention provides a pharmaceutical granule comprising cimetidine and 2-20% (w/w) relative to the cimetidine of a co-polymer of dimethylaminoethylmethacrylate and neutral methacrylic acid esters. Compositions of this invention have good palatability and dissolution characteristics.Type: GrantFiled: January 4, 1989Date of Patent: February 23, 1993Assignee: Smith Kline & French Laboratories Ltd.Inventor: Kevin E. Pearmain
-
Patent number: 5189066Abstract: The subject invention involves compositions, consisting essentially of the drug active 1-3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl-5-hexyn-1-one (tebufelone) at a concentration of at least about 15%, and the balance a pharmaceutically-acceptable vehicle. The vehicle is formulated such that the compositions are homogeneous liquids at 37.degree. C. and provide good solubilization of the drug active.Type: GrantFiled: July 19, 1991Date of Patent: February 23, 1993Assignee: The Procter & Gamble CompanyInventors: Gary R. Kelm, Alan E. Bruns
-
Patent number: 5133974Abstract: An extended release pharmaceutical formulation adapted to approach zero order release of drug over a 12 to at least 24 hour period, comprised of a mixture of 0 to aobut 50% of an immediate release particle containing a drug, inert substrate and binder, coated with talc and up to 100% of an extended release particle comprising the immediate release particle coated with a dissolution modifying system containing plasticizers and a film forming agent.Type: GrantFiled: January 24, 1990Date of Patent: July 28, 1992Assignee: KV Pharmaceutical CompanyInventors: George N. Paradissis, James A. Garegnani, Roy S. Whaley
-
Patent number: 5032572Abstract: Polymers from ethylenically unsaturated monomers, cross-linked by a substituted divinylazobenzene are useful as pharmaceutical compositions for the delivery of medicaments. The polymers are degraded by the enzymes of the upper gastrointestinal tract or are transferred intact past the upper gastrointestinal tract, to deliver the medicament to the large intestine. In particular, the polymers contain divinylazobenzene compounds of the formulae ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of H, (except that R.sub.1 and R.sub.2 are not both H), Cl, Br, I, NO.sub.2, NH.sub.2, RO, ArO, COOH or salts thereof, COOR, COOAr, CHO, COR, SO.sub.3 H or salts thereof, R or Ar and wherein R is alkyl of up to 18 carbon atoms and Ar is mono- or bicyclic aryl of up to 15 carbon atoms.Type: GrantFiled: August 12, 1988Date of Patent: July 16, 1991Assignees: Medical College of Ohio, Bowling Green State UniversityInventors: Murray Saffran, Douglas C. Neckers
-
Patent number: 4983605Abstract: A pharmaceutical composition comprising a benzoyl urea compound (A) selected from the group consisting of a benzoyl urea compound (I) having the formula: ##STR1## wherein X is a halogen atom, a nitro group or a trifluoromethyl group, provided that when Y is a nitro group, X is a halogen atom or a nitro group, Y is a hydrogen atom, a halogen atom, a nitro group or a trifluoromethyl group, Z.sub.1 is a halogen atom or a trifluoromethyl group, Z.sub.2 is a hydrogen atom or a halogen atom, and A is a .dbd.CH-- group or a nitrogen atom, and a benzoyl urea compound (II) having the formula: ##STR2## wherein each of X.sub.1 and X.sub.2 is a hydrogen atom, a halogen atom or a nitro group, provided that when Y is a nitro group, X.sub.Type: GrantFiled: October 20, 1987Date of Patent: January 8, 1991Assignees: Ishihara Sangyo Kaisha Ltd., The Green Cross CorporationInventors: Nobuo Kondo, Masahiro Kikuchi, Tsunetaka Nakajima, Masahiro Watanabe, Kazumasa Yokoyama, Takahiro Haga, Nobutoshi Yamada, Hideo Sugi, Toru Koyanagi
-
Patent number: 4885290Abstract: Disclosed herein is an immunoregulator comprising a derivative of estradiol represented by the formula (I), which immunoregulator has a small influence to the non-specific immunoreactions in general and gives a specific influence to the immunoreactions against an isoantibody.Type: GrantFiled: October 29, 1987Date of Patent: December 5, 1989Assignee: Kureha Kagaku Kogyo Kabushiki KaishaInventors: Kiro Asano, Tadahiro Matsudaira, Humio Tamura, Toichi Suzuki, Hisayuki Wada
-
Patent number: 4766148Abstract: Biphenylylpropionic acid derivatives of the formula: ##STR1## wherein R is an alkylcarbonyloxyalkyl group or an alkenylcarbonyloxyalkyl group having the formula: ##STR2## wherein R.sup.1 is a lower alkyl group having 1 to 5 carbon atoms and R.sup.2 is an alkyl group having 1 to 15 carbon atoms or an alkenyl group having 2 to 8 carbon atoms, or a lactone having the formula: ##STR3## wherein R.sup.3 and R.sup.4 are hydrogen atom or a lower alkyl group having 1 to 2 carbon atoms, and n is an integer of 1 or 2. The compounds have excellent anti-inflammatory, analgesic and antipyretic activities. Moreover, the compounds have no irritation, rapid and long-acting, and high safety margin.Type: GrantFiled: June 7, 1985Date of Patent: August 23, 1988Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Katsuhiro Uchida, Shozo Masumoto, Masao Tohno, Mitsuo Mimura, Makoto Okumura
-
Patent number: 4678812Abstract: An improved method for preparing tablets useful in diagnostic applications, utilizing trehalose as an excipient and stabilizer, is provided.Type: GrantFiled: May 30, 1986Date of Patent: July 7, 1987Assignee: E. I. Du Pont De Nemours and CompanyInventors: Ernest Bollin, Jr., Mark G. Fletcher
-
Patent number: 4663308Abstract: Polymers from ethylenically unsaturated monomers, cross-linked by a substituted or unsubstituted divinylazobenzene are useful as carriers or capsules for medicaments, which are degraded by the enzymes of the upper gastrointestinal tract or which must be transferred intact past the upper gastrointestinal tract, to deliver the medicament to the large intestine.Polymers containing monomeric units of the formulaH.sub.2 C.dbd.CH--C.sub.6 H.sub.4 --N.dbd.N--M,wherein M is the residue of an amino-containing medicament, are useful as carriers for therapeutic agents or as therapeutic agents per se.Type: GrantFiled: July 18, 1984Date of Patent: May 5, 1987Assignees: Medical College of Ohio, Bowling Green State UniversityInventors: Murray Saffran, Douglas C. Neckers
-
Patent number: 4614648Abstract: The invention relates to a process for manufacturing effervescent tablets consisting in the steps of careful humidifying of the acid+base mixture, pre-drying and final drying and granulating.It has been found that these operations can be performed in a single apparatus, either integrally in fluid bed, or with vacuum-drying.Type: GrantFiled: August 20, 1984Date of Patent: September 30, 1986Inventor: Jean Bru
-
Patent number: RE33086Abstract: The invention relates to a process for manufacturing effervescent tablets consisting in the steps of careful humidifying of the acid+base mixture, pre-drying and final drying and granulating.It has been found that these operations can be performed in a single apparatus, either integrally in fluid bed, or with vacuum-drying.Type: GrantFiled: July 10, 1987Date of Patent: October 10, 1989Inventor: Jean Bru